2017 Publications

The LMC skills, confidence & preparedness index (SCPI): development and evaluation of a novel tool for assessing self-management in patients with diabetes

This study presents the development and initial psychometric evaluation of the SCPI (Skills, Confidence and Preparedness Index) in measuring an individual’s diabetes self-management in three areas: Knowledge of the skill, Confidence in performing the skill, and Preparedness in implementing the skill.

The LMC Skills, Confidence & Preparedness Index (SCPI): development and evaluation of a novel tool for assessing self-management in patients with diabetes

Glycemic improvement with a fixed-dose combination of DPP-4 inhibitor + metformin in patients with type 2 diabetes (GIFT study)

Does it matter to overall control whether your take pills once a day or twice?  Whether you take two different types of tablets or one combined tablet?  This study looks at the changes in glucose control in individuals with type 2 diabetes after switching from separate dual therapy of metformin and DPP-4 inhibitor to a fixed-dose combination (FDC) of metformin + DPP-4 inhibitor following the introduction of the combination in the provincial formulary. The study showed that the switch to FDC of metformin+DPP-4 inhibitor was associated with a significant improvement in A1C.

Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study)

Effect of dapagiflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: A retrospective cohort analysis

In randomized clinical trials, the SGLT2 inhibitor dapagliflozin was shown to improve glycemic control, weight and blood pressure.  However, there is little real-world evidence on the effectiveness of dapagliflozin in real-world clinical practice.   This study investigated real-world important clinical outcomes of individuals with type 2 diabetes who started dapagliflozin as part of usual clinical therapy in a referral-based endocrinology practice.  Patients initiating dapagliflozin had a significant 3 to 6-month improvement in HbA1c, weight and blood pressure.   

Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis

Lowest glucose variability and hypoglycemia are observed With the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study)

This cohort study compares glucose variability with the use of continuous glucose monitoring (CGM) in patients with well-controlled type 2 diabetes currently using 4 common insulin regimens: basal insulin + oral drugs (BO), basal insulin +glucagon-like peptide 1 receptor agonist (GLP-1 RA)(BGLP), premixed insulin (PM), and basal-bolus insulin (BB).

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)